December 2002
Worldwide Biotech;Dec2002, Vol. 14 Issue 12, p4
Trade Publication
Reports on a patent issued to cardiovascular drug discovery and development company Medicure Inc. by the U.S. Patent Office to protect the composition of several of the company's newly discovered therapeutics, as of December 2002.


Related Articles

  • MEDICURE GETS PATENT NOTICE OF ALLOWANCE FOR THERAPEUTICS.  // Worldwide Biotech;Sep2002, Vol. 14 Issue 9, p5 

    Reports on the Notice of Allowance received by Medicure Inc. from the U.S. Patent Office for a composition of matter patent covering several of the company's discovered therapeutics for use in treatment of cardiovascular diseases.

  • MEDICURE APPROVED TO BEGIN PHASE II/III HYPERTENSION TRIALS.  // Worldwide Biotech;Sep2003, Vol. 15 Issue 9, p2 

    Reports on the approval received by Medicure Inc. from the Therapeutic Products Directorate in Canada to commence a Phase II hypertension trial as part of the development program for the second clinical candidate of the company, MC-4232.

  • MEDICURE GETS FDA/TPD APPROVALS FOR MC-1 PHASE II TRIAL.  // Worldwide Biotech;Jan2004, Vol. 16 Issue 1, p1 

    States that Medicure Inc., a Winnipeg, Manitoba-based cardiovascular drug company, has received approval from the United States Food and Drug Administration and the Canadian Therapeutic Product Directorate to initiate its Phase II clinical study to treat patients with the company's MC-1 drug.

  • Medicure annual net loss decreases.  // PharmaWatch: CNS;Nov2011, Vol. 10 Issue 11, p17 

    The article reports that the net loss of Medicure Inc. for year ending May 31, 2011 has decreased compared to its net loss for year ending in May 31, 2010.

  • Financings Roundup.  // BioWorld Today;3/2/2010, Vol. 21 Issue 40, p3 

    The article reports on an agreement by Medicure Inc. with the lender under its secured debt financing agreement of September 17, 2007, to further defer required payments of about 2.1 million U.S. dollars until March 14, 2010.

  • Medicure reports annual net income.  // PharmaWatch: CNS;Nov2012, Vol. 11 Issue 11, p22 

    The article reports on the financial results of specialty pharmaceutical firm Medicure Inc. in its fiscal year ending May 31, 2012, including a net income of 23.38 million Canadian dollar against a net loss of 1.63 million Canadian dollar in the year ending March 31, 2011.

  • Patently Standard? Wong, William // Electronic Design;9/2/2002, Vol. 50 Issue 18, p63 

    Focuses on the importance of setting standards in assigning patents in electronics in the U.S. as of September 2, 2002. Java Community Process started by Sun Microsystems; Reasonable and non-discriminatory licensing; Assignment of many software patents by the U.S. Patent and Trademark Office.

  • A first refusal isn't necessarily final. McKee, Bradford // Nation's Business;Feb93, Vol. 81 Issue 2, p10 

    Demonstrates that an initial rejection to a patent application is not necessarily final. Case of Barbara Stenger; Board of Patent Appeals of the United States Patent Office; Process of the appeal; Composition of the board; Percentage of responsible applications which are granted; Contact...

  • FYI...U.S. patents issued by material type.  // Plastics News;12/15/1997, Vol. 9 Issue 42, p3 

    Presents a graph depicting the United States patents issued by material type through November 18, 1997.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics